Research Publications

Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ

Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy.

Meine TJ, Al-Khatib SM, Alexander JH, Granger CB, White HD, Kilaru R, Williams K, Ohman EM, Topol E, Califf RM

A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data.

Topol EJ

Towards precise classification of cancers based on robust gene functional expression profiles.

Guo Z, Zhang T, Li X, Wang Q, Xu J, Yu H, Zhu J, Wang H, Wang C, Topol EJ, Wang Q, Rao S

Aspirin resistance and a single gene.

Jefferson BK, Foster JH, McCarthy JJ, Ginsburg G, Parker A, Kottke-Marchant K, Topol EJ

Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting.

Chan AW, Yadav JS, Bhatt DL, Bajzer CT, Gum PA, Roffi M, Cho L, Agah R, Topol EJ

Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.

Gurm HS, Rajagopal V, Fathi R, Vivekanathan D, Yadav JS, Bhatt DL, Ellis SG, Lincoff AM, Topol EJ

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial).

Chew DP, Lincoff AM, Gurm H, Wolski K, Cohen DJ, Henry T, Feit F, Topol EJ, REPLACE-2 Investigators

Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials).

Rebeiz AG, Johanson P, Green CL, Crater SW, Roe MT, Langer A, Giugliano RP, Lincoff AM, Newby LK, Harrington RA, Topol EJ, Califf RM, Wagner GS, Krucoff MW

Cholesterol, racial variation and targeted medicines.

Topol EJ